recombination

The University of Maryland, Baltimore is now participating in Horizon's "Targeting Cancer Consortium," in which the company supplies its gene-engineering platform to academic researchers, who create cellular disease models that Horizon in-licenses and sells to drug makers.

CalTech's Peter Bossaerts and colleagues studied whether giving participants equal shares of an invention, and the right to trade them, is better than existing patent models. Bossaerts discussed some of the study's implications for current patent-based economies in a BTW interview.